November 1, 2021 • 48 mins
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Eyal Talor, Ph.D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmune diseases, and infectious diseases. In today’s program, Hofland and Talor are talking about one of these agents, an investigational drug called leukocyte interleukin, or Multikine®
Multikine® is currently in late-stage development and is being investigated as a possible new adjuvant therapy for patients diagnosed with head-and-neck cancer and cervical dysplasia.
The published results of clinical studies, including a recently concluded Phase 3 study, are very promising in patients diagnosed with head-and-neck cancer. Patients treated with this new anticancer agent in combination with standard of care (SOC) versus standard of care alone had an overall survival benefit of 14.1% at five years. These results exceeded the predefined 10% overall survival benefit set out for the study population as a whole.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Multikine® is currently in late-stage development and is being investigated as a possible new adjuvant therapy for patients diagnosed with head-and-neck cancer and cervical dysplasia.
The published results of clinical studies, including a recently concluded Phase 3 study, are very promising in patients diagnosed with head-and-neck cancer. Patients treated with this new anticancer agent in combination with standard of care (SOC) versus standard of care alone had an overall survival benefit of 14.1% at five years. These results exceeded the predefined 10% overall survival benefit set out for the study population as a whole.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Mark as Played
Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
Death, Sex & Money
Anna Sale explores the big questions and hard choices that are often left out of polite conversation.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.